---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-22-000009"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2022-02-11T23:59:59+00:00"
generated_at: "2026-06-27T08:58:06.869165+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine reports 2021 INGREZZA sales of $1.1B, guides 2022 sales $1.25-1.35B

## Summary
- Total revenue FY 2021 $1.13B (+8% YoY); INGREZZA net sales $1.09B (+10% YoY).
- GAAP net income $89.6M ($0.92 diluted EPS); non-GAAP net income $185.8M ($1.90 diluted EPS).
- Q4 2021 GAAP net loss $7.3M ($0.08 loss per share) due to $100M Sosei Heptares upfront fee.
- 2022 INGREZZA guidance $1.25-1.35B (+20% YoY midpoint); minimal federal cash taxes expected in 2022.
- Phase III KINECT-HD valbenazine met primary endpoint; sNDA for Huntington chorea planned H2 2022.

## SEC filing metadata
- accession: 0000914475-22-000009
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2022-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447522000009/0000914475-22-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447522000009/nbix-20220211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-22-000009
- JSON: https://secwatch.observer/filing/0000914475-22-000009.json
- Plain text: https://secwatch.observer/filing/0000914475-22-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.